Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvER-ILD 2
2022-501335-16-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in interstitial lung disease (ILD) comparing Rituximab with Placebo (2 arms). Primary endpoint: Change in FVC (mL) from baseline to 6 months. Planned start Oct 2022; status: authorised.
02
Drugs
rituximab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on 2022-501335-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501335-16-00.